Ticagrelor: agonising over its mechanisms of action.
Ticagrelor: agonising over its mechanisms of action.
复制标题
DOI：
10.1182/blood-2016-10-743930
复制
发表时间：
2016-12
期刊：
影响因子：
20.3
通讯作者：
William A. E. Parker;R. Storey
中科院分区：
文献类型：
--
作者：
William A. E. Parker;R. Storey
与氯吡格雷相比，替格瑞洛在治疗急性冠脉综合征 (ACS) 患者方面具有优越的功效，包括显着减少心血管死亡，这引发了人们对这种优越性的潜在机制的探索，例如本期《Blood》中 Aungraheeta 等人的工作。他们描述了替格瑞洛与 P2Y12 受体相互作用的新特性，并通过平衡核苷转运蛋白 1 (ENT1) 抑制细胞腺苷摄取来证实腺苷介导的作用。1
The superior efficacy of ticagrelor compared with clopidogrel in the management of patients with acute coronary syndrome (ACS), including a significant reduction in cardiovascular death, has led to a search for potential mechanisms for this superiority, such as in this issue of Blood in the work of Aungraheeta et al. They describe a novel property of ticagrelor in its interaction with the P2Y12 receptor as well as confirming adenosine-mediated effects through inhibition of cellular adenosine uptake via equilibrative nucleoside transporter 1 (ENT1).1